 Truist has initiated coverage on Verastem Oncology Inc NASDAQ: VSTM with a Buy rating and 6.00 price target, equivalent to approximately 350 upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is undervalued given its programs in. 